GlassScriptPhysician profile
Ayman Boutros
NPI 1366530131
$4,995.33
in general payments reported to CMS, 2019-2025
25 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $414 · 2021: $573 · 2022: $1,135 · 2023: $620 · 2024: $738 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.29 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Notal Vision, INC. | $568.77 | 2022 | |
| Alcon Vision LLC | $487.59 | 2019-2025 | Clareon Panoptix Pro, Hydrus Microstent, Argos |
| Novartis Pharmaceuticals Corporation | $481.26 | 2019-2023 | |
| Allergan, INC. | $364.96 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $346.21 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $307.51 | 2019-2023 | Tecnis Iol |
| Kala Pharmaceuticals, INC. | $287.65 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $203.91 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $196.63 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $150.64 | 2024-2025 | Xdemvy |
| Rxsight INC | $137.53 | 2023-2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $132.52 | 2022-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $104.90 | 2019-2022 | |
| Alimera Sciences, INC. | $91.14 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $64.46 | 2024-2025 | Eylea Hd |
| Glaukos Corporation | $59.65 | 2025 | Idosetr |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Astellas Pharma US INC | $33.80 | 2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $30.71 | 2019-2020 | |
| Harrow Eye, LLC | $28.79 | 2025 | Vevye |
| Sight Sciences, INC. | $28.32 | 2022 | |
| Ani Pharmaceuticals, INC. | $28.30 | 2025 | Iluvien |
| Ocular Therapeutix, INC. | $22.07 | 2022 | |
| Lensar, INC. | $15.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Boutros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.